Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
2021 · Cell Death and Disease · 53 citations
https://doi.org/10.1038/s41419-021-03844-z
L
Liang Ma
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
73
Papers
1.2K
Citations
18
h-index
31
i10-index
Liang Ma is an academic researcher from First Affiliated Hospital Zhejiang University. The author has contributed to research in topics: Ubiquitin and proteasome pathways & Natural Compounds in Disease Treatment & Biological Activity of Diterpenoids and Biflavonoids. The author has an h-index of 18, co-authored 63 publications.
ORCID: 0000-0001-9131-4512Papers by this author
worksSystematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis
2020 · EBioMedicine · 23 citations
https://doi.org/10.1016/j.ebiom.2020.102689
Anti-breast cancer activity of a novel genetically engineered fusion protein composed of HER2 affibody and proapoptotic peptide R8-KLA
2025 · Medical Oncology · 2 citations
https://doi.org/10.1007/s12032-025-02707-3
Circulating microbiome DNA features and its effect on predicting clinicopathological characteristics of patients with colorectal cancer
2025 · Journal of Translational Medicine · 1 citations
https://doi.org/10.1186/s12967-025-06164-4
Circulating CD34 <sup>+</sup> Fibroblast Progenitors Engaged in Heart Fibrosis of Allograft
2026 · Circulation Research · 0 citations
https://doi.org/10.1161/circresaha.125.326558
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat